linjc16/ctgov huggingface dataset:
Feasibility of AI-based Heart Function Prediction Model Using CXR

Study Overview
=================
Brief Summary
-----------------
The investigators will develop an artificial intelligence model to predict left ventricular ejection fraction using chest radiographic images and transthoracic echocardiography data.

Detailed Description
-----------------
Echocardiography should be considered at an early stage in patients who have first developed heart failure or who do not have information about heart function, but the examination may be delayed due to lack of time and manpower in the actual medical field. Primary Objective: Use chest radiographs to predict the left ventricular ejection fraction

Official Title
-----------------
Feasibility of Artificial Intelligence-based Heart Function Prediction Model Using Chest Radiography

Conditions
-----------------
Chest X-ray for Clinical Evaluation

Intervention / Treatment
-----------------
* Diagnostic Test: Scanning Chest X-rays and performing AI algorithms on images


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults who are 20 years and older Patient who visited the emergency room or outpatient clinic due to dyspnea and chest pain Exclusion Criteria: Patient refusal Uncertain radiographs or transthoracic echocardiography Uncertain tests results

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Scanning Chest X-rays and performing AI algorithms on images|Chest X-Rays; AI CNNs; Results|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Left Ventricular Ejection Fraction < 40% | Evaluate the performance of chest X-ray based artificial intelligence algorithms to identify individuals with reduced ejection fraction (<40%) | Within two weeks of chest X-ray |
Construction of a Database for TMA

Study Overview
=================
Brief Summary
-----------------
Information about patients was collected by reviewing the Hitech case system and telephone and outpatient follow-up, and the case database was constructed by Epidata software. The sample size is expected to be 200 cases, the participating hospital is the First Affiliated Hospital of Soochow University, and the study time frame is from Dec 1, 2022, to Nov 31, 2027. The observation indexes of the study include the basic information of patients' age and gender and the clinical-related data of thrombotic microangiopathy.

Official Title
-----------------
Construction of a Database for Thrombotic Microangiopathy

Conditions
-----------------
Thrombotic Microangiopathies

Intervention / Treatment
-----------------
* Other: collection data


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient has elevated lactate dehydrogenase to more than twice the baseline value, platelets less than 20 or decreased by more than 50% within 24 hours, and more than 2% of schistocytes visible on a peripheral blood smear. Alternatively, pathological sections show extensive micro thrombosis. Exclusion Criteria: The investigator considers the subject unable or unwilling to cooperate with the study procedures.
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TMA<br>TMA patients | Other: collection data<br>* collection data<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with stroke | Stroke was assessed with MRI imaging. | 5 years from the time of entering the database. |
Lay-user Trial of the iGlucose Blood Glucose Monitoring System

Study Overview
=================
Brief Summary
-----------------
Evaluation of the iGlucose Blood Glucose Monitoring System in the hands of lay users

Detailed Description
-----------------
A non-randomized, prospective study of recruited subjects with diabetes. Subjects will include those with type I or type II diabetes of various duration and those who are naive to self-testing of blood glucose. Subjects will use provided instructions-for-use to undergo self-training on the use of the device and will then self-test their blood glucose level. Results will be compared to those obtained by a lab glucose analyzer.

Official Title
-----------------
A Lay User Study of the iGlucose, a Device for Self-Monitoring of Blood Glucose (SMBG), Marketed by the Smart Meter Corporation

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Device: Blood glucose monitor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Be 12 years of age and older Have pre-existing diagnosis of diabetes Be able to read and understand English Agree to participate in the study Be able and willing to provide informed consent Exclusion Criteria: Do not meet Inclusion Criteria With Hemophilia or any other bleeding disorder With any condition which in the opinion of the Investigator may place the subject or site staff at excessive risk With physical condition/limitation preventing the use of SMBG on their own

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with diabetes<br> | Device: Blood glucose monitor<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of blood glucose measurements as performed by lay users |  | 10 minutes to produce self blood result and to perform lab comparative method | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment by lay users of the ease of use of the iGlucose Blood Glucose Monitoring System |  | 2 -3 hours of going through a self-training session and producing an assessment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes, Blood Sugar
Clinical Application of Wearable Magnet Tracking System for Capsule Endoscopes

Study Overview
=================
Brief Summary
-----------------
The investigators developed a wearable magnet tracking system, which provided a non-invasive and high accuracy method for capsule endoscopes localization. Data fusion from multiple sensors expanded positioning range and proposed localization algorithm overcame shortcomings of existing systems. This clinical trial was conducted to verify effectiveness and stability of the tracking system.

Official Title
-----------------
Clinical Application of Wearable Magnet Tracking System for Capsule Endoscopes

Conditions
-----------------
Capsule Endoscopes

Intervention / Treatment
-----------------
* Device: wearable magnet tracking system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged between 18 and 75 agree to give written informed consent Exclusion Criteria: dysphagia or symptoms of gastric outlet obstruction, suspected or known intestinal stenosis, overt gastrointestinal bleeding, history of upper gastrointestinal surgery or abdominal surgery altering gastrointestinal anatomy, or postabdominal radiation congestive heart failure, renal insufficiency, under therapeutic anticoagulation, in poor general condition (American Society of Anesthesiologists class III/IV), claustrophobia, metallic parts, a pacemaker or other implanted electromedical devices, or artificial heart valves pregnancy or suspected pregnancy exclusion criteria for standard magnetic resonance imaging examination such as the presence of surgical metallic devices, even though its low magnetic field technically would not interferewith such devices currently participating in another clinical study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Device Feasibility
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: wearable magnet tracking system<br> | Device: wearable magnet tracking system<br>* In this group, wearable magnet tracking system was used.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The duration of time | the length of time of the tracking system used in continuous acquisition of the magnetic field strength values | 12 months |
Preemptive Acetaminophen for Postoperative Pain Control Following Minimally Invasive Hysterectomy

Study Overview
=================
Brief Summary
-----------------
This study is investigating whether administration of acetaminophen the day before surgery improves post operative pain following minimally invasive hysterectomy. Patients will receive either acetaminophen or placebo to take twice per day the day prior to their scheduled surgery. The morning of surgery all participants will receive oral acetaminophen at least 30 minutes prior to surgery. The investigators will examine whether there is a difference in post operative pain between the two groups.

Official Title
-----------------
Preemptive Acetaminophen for Postoperative Pain Control Following Minimally Invasive Hysterectomy: a Randomized Control Trial

Conditions
-----------------
Post Operative Pain

Intervention / Treatment
-----------------
* Drug: Acetaminophen
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergoing minimally invasive hysterectomy for benign indications Exclusion Criteria: acetaminophen allergy liver disease kidney disease consume >3 alcoholic beverages per day weigh <50 kilograms report daily opiate use contraindication to acetaminophen used acetaminophen within 24 hours of surgery undergoing a concomitant pelvic reconstructive procedure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Preemptive acetominophen<br>Acetaminophen 975mg BID the day before surgery and again 30-60 minutes preoperatively | Drug: Acetaminophen<br>* Preemptive acetaminophen the day before surgery<br>|
| Placebo Comparator: Standard of care<br>Placebo the day before surgery and acetaminophen 30-60 minutes preoperatively | Drug: Placebo<br>* Preemptive placebo the day before surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-operative opioid use | The total amount of opiate consumption in the immediate postoperative period will be recorded. Per standard protocol, patient's will be ordered for pain medication to receive on an as needed basis. The amount of both oral and IV opioids consumed by the patient will be converted to total morphine equivalents. As such, post operative opioid use will be used as a proxy for degree of post operative pain. | 4 hours |
Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether Campath-1H induction therapy and the associated lymphocyte depletion will permit long-term, rejection free renal allograft function in the absence of maintenance calcineurin inhibitor (CI) therapy.

Official Title
-----------------
Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation

Conditions
-----------------
Primary Renal Transplant

Intervention / Treatment
-----------------
* Drug: Calcineurin inhibitor withdrawal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: received a renal transplant, induction with Campath-1H, and at least 2 months of calcineurin inhibitor therapy, CellCept, and prednisone. Exclusion Criteria: Recipients of HLA-identical living-donor renal transplants; PRA value >20% within 30 days of transplant; GFR <40ml/min; multi-organ transplant;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: 1<br>Standard of Care CNI immunosuppression | |
| Experimental: 2<br>Calcineurin inhibitor withdrawal | Drug: Calcineurin inhibitor withdrawal<br>* stopping tacrolimus or cyclosporine in subjects who received Campath-1H induction therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Biopsy Proven Rejection |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum Creatinine at 36 Months (End of Study) |  | 36 months +/- 60 days |
Safety and Efficacy Study of Duet TRS

Study Overview
=================
Brief Summary
-----------------
The objectives of this clinical trial are the overall performance and safety of the ENDO GIA Staplers with ENDO GIA SULUs with Duet TRS TM.

Official Title
-----------------
A Prospective, Single-Center Investigation of the Safety and Performance of the ENDO GIA Staplers With ENDO GIA Single Use Loading Units With DUET TRS TM in a Gastric Bypass Procedure

Conditions
-----------------
Roux En Y Gastric Bypass

Intervention / Treatment
-----------------
* Device: Duet TRS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient must be 18-65 years of age. The patient has a BMI of 40-60 kg/m2 or 35-40 kg/m2 with comorbidities The patient must be willing and able to participate in the study procedures and able to understand and sign the informed consent. Exclusion Criteria: The procedure is needed as revision bariatric surgery or the patient has had prior gastric surgery (nissen fundoplication, hiatal hernia, etc) The patient is pregnant. The patient has an active, or history of, infection at the operative site. The patient is unable or unwilling to comply with the study requirements, follow-up schedule, or to give valid informed consent. Patient has an abdominal ventral hernia The patient has a history of liver disease The patient has a history of drug or alcohol abuse The patient has a history of venous thrombosis or pulmonary embolism The patient has a history of coagulopathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Duet TRS<br>Subjects receive Duet TRS | Device: Duet TRS<br>* Patients will have their gastric pouch created with ENDO GIA staplers with Single Use Loading Units with Duet TRS.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Adverse Events. |  | Day 30 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Operating Room (OR) Time | OR time was captured in minutes, with time starting at the first port placement and concluding at the removal of the last port. | Day 0 | 
| Length of Hospital Stay | Days spent in the hospital | Day 2 (Approximately 1.5 days post randomization) | 
| Incidence of Stapler 'Misfires' | The incidence of stapler misfires was captured as the number of patients with misfires. The types of misfires that were captured were less than B shaped staples, incomplete staple line and stripping of the rack teeth. | Day 0 |
Coagulation Factors, Cytokines and Tissue Injury Markers in Sepsis

Study Overview
=================
Brief Summary
-----------------
In an effort to better understand the interaction between the different mediators, the investigators propose to examine the time course of mediators, the indexes of organ injury and the coagulation cascade.

Detailed Description
-----------------
All patients admitted to the ICU (Including VA Medical Center, University Hospital and Presbyterian hospital) will be screened for enrollment in the study. Patients who have the diagnosis of sepsis will be asked to volunteer. We will match sepsis patients with other ICU patients without the diagnosis of sepsis. The latter will also be asked to volunteer. Patients will be stratified into three groups: Sepsis SIRS of non-septic origin Other ICU patients Routine laboratory data and clinical data (see flow sheet) will be collected. The plasma or serum will be frozen separately until the target number of patients is met. Measurements of inflammatory mediators and other cytokines/injury markers will be carried out at that point.

Official Title
-----------------
Temporal Behavior of Coagulation Factors,Cytokines and Tissue Injury Markers in Sepsis: Validation of Extracellular Histones

Conditions
-----------------
Sepsis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admission to the ICU Exclusion Criteria: No blood draws scheduled Hemoglobin level < 6.5 gm/dl

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Histones, organ failure, sepsis
'Activity Pacing' in PLWH With Fatigue Symptoms.

Study Overview
=================
Brief Summary
-----------------
Physical activity helps to improve health and prevent chronic diseases. However, the fatigue usually hampers the training and execution of physical exercises, especially in people with chronic fatigue syndromes (CFCs), such as persons living with HIV (PLWH). We hypothesize that the activity pacing, i.e. the strategy to optimize daily physical activity into manageable exercises in a way that should not exacerbate fatigue symptoms, may help a progressive improvement in physical activity of a group of PLWH with fatigue symptoms. Motivation and adherence to exercise will be monitored through the use of digital supports.

Official Title
-----------------
ActiPacMAN: 'Activity Pacing' in PLWH With Fatigue Symptoms. Monitoring Through the Combined Use of Actigraphy and Mobile App Notifications

Conditions
-----------------
Hiv

Intervention / Treatment
-----------------
* Behavioral: Home-based physical activity


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: of age ≥18 years; either sedentary or already practicing mild/moderate physical activity (at least 150 minutes of moderate-intensity physical activity throughout the week); able to sign the informed consent. Exclusion Criteria: The study will exclude HIV+ individuals: with any HIV-related disease requiring hospitalization in the 6 weeks before enrolment; with medical conditions (e.g. neurologic, muscular-skeletal, cardiovascular diseases) contraindicating non agonistic exercise, as established by a sport medicine specialist; currently abusing of substance or alcohol; already performing physical activity at higher level than the current WHO recommendations (30 minutes of moderate activity 5 times a week).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental Group<br>Participants will follow a personalized activity pacing program for 16 weeks with the support of a heath band and a mobile application for tablet | Behavioral: Home-based physical activity<br>* Participants will follow a personalized activity pacing program<br>|
| No Intervention: Control Group<br>Participants will follow a personalized activity pacing program for 16 weeks without any other support | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Activity pacing improvement | To compare the improvement in the physical fitness between the Experimental Group and Control Group | 16 week |